Please login to the form below

Not currently logged in

AZ gets orphan status for selumetinib in thyroid cancer

Drug already in phase III testing for KRAS-mutant advanced NSCLC

AstraZeneca headquarters

AstraZeneca has claimed orphan drug status in the US for selumetinib - one of its second-tier oncology prospects - as a treatment for advanced differentiated thyroid cancer (DTC).

Selumetinib is a MEK 1/2 inhibitor that is already in phase III testing for KRAS-mutant advanced non-small cell lung cancer (NSCLC) and a phase II trial in children and adolescents with neurofibromatosis type 1, a genetic disorder that causes tumours to grow along nerves.

The drug is being developed for the small proportion of patients with DTC who do not respond to treatment with radioactive iodine (RAI) - the recommended therapy for DTC cases that have spread and have a high risk of recurrence.

Non-responders to RAI typically do not express a protein - known as sodium/iodine symporter (NIS) - which allows the iodine to be taken up by thyroid cells. AZ has shown that selumetinib increases the expression of NIS and so could be an add-on treatment for patients who do not respond well to RAI.

Selumetinib is currently being tested in the ASTRA study, a phase III trial which is comparing the complete remission rate following a 5-week course of selumetinib or placebo and single dose adjuvant radioactive iodine therapy in patients with DTC.

There are around 60,000 cases of DTC in the US each year, well below the threshold of 200,000 patients that is used to define orphan status. A drug with orphan status attracts grants, tax incentives and the extension of exclusive marketing rights to a drug by seven years.

Orphan drugs accounted for $54bn in sales in the US last year and are expected to reach $60bn in 2016, according to EvaluatePharma data.

The drug is not one of the top oncology prospects at AZ - a group that includes recently-approved NSCLC therapy Tagrisso (osimertinib), Lynparza (olaparib) for ovarian cancer and PD-L1-targeting immuno-oncology candidate durvalumab (MEDI4736).

AZ had also been developing selumetinib in uveal melanoma, but abandoned that programme last year after the drug failed to meet its objectives in a mid-stage clinical trial. Prior to that some analysts had suggested it could become a $1bn product, but now most peak sales predictions fall below the $500m mark.

Article by
Phil Taylor

13th May 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....